Literature DB >> 27141405

FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy.

Alan Serrels1, Margaret C Frame1.   

Abstract

Evading the antitumor immune response is important for the survival and progression of cancer. Recently, we identified an unexpected role for nuclear Focal Adhesion Kinase (FAK) activity in the control of tumor Treg levels and immune evasion by regulating chemokine and cytokine transcription in cancer cells. We proposed a potentially new purpose for FAK kinase inhibitors, which can cause immune-mediated tumor regression.

Entities:  

Keywords:  Cancer immunity; Focal Adhesion Kinase; checkpoint blockade; chemokine transcription; tumor microenvironment

Year:  2016        PMID： 27141405      PMCID： PMC4839353          DOI： 10.1080/2162402X.2015.1119356

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

Review 2.  The role of focal-adhesion kinase in cancer - a new therapeutic opportunity.

Authors:  Gordon W McLean; Neil O Carragher; Egle Avizienyte; Jeff Evans; Valerie G Brunton; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

Review 3.  Nuclear FAK: a new mode of gene regulation from cellular adhesions.

Authors:  Ssang-Taek Steve Lim
Journal:  Mol Cells       Date:  2013-05-16       Impact factor: 5.034

4.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

Authors:  Walter Gregory Roberts; Ethan Ung; Pamela Whalen; Beth Cooper; Catherine Hulford; Christofer Autry; Daniel Richter; Earling Emerson; Jing Lin; John Kath; Kevin Coleman; Lili Yao; Luis Martinez-Alsina; Marianne Lorenzen; Martin Berliner; Michael Luzzio; Nandini Patel; Erika Schmitt; Susan LaGreca; Jitesh Jani; Matt Wessel; Eric Marr; Matt Griffor; Felix Vajdos
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

5.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

6.  Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer.

Authors:  Abdulkader Albasri; Wakkas Fadhil; John H Scholefield; Lindy G Durrant; Mohammad Ilyas
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

7.  Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Authors:  Alan Serrels; Tom Lund; Bryan Serrels; Adam Byron; Rhoanne C McPherson; Alexander von Kriegsheim; Laura Gómez-Cuadrado; Marta Canel; Morwenna Muir; Jennifer E Ring; Eleni Maniati; Andrew H Sims; Jonathan A Pachter; Valerie G Brunton; Nick Gilbert; Stephen M Anderton; Robert J B Nibbs; Margaret C Frame
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

8.  Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.

Authors:  Paula D Bos; George Plitas; Dipayan Rudra; Sue Y Lee; Alexander Y Rudensky
Journal:  J Exp Med       Date:  2013-10-14       Impact factor: 14.307

9.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701
  9 in total
  6 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  FAK alternative splice mRNA variants expression pattern in colorectal cancer.

Authors:  Christel Devaud; Anne-Françoise Tilkin-Mariamé; Alix Vignolle-Vidoni; Philippine Souleres; Alexandre Denadai-Souza; Corinne Rolland; Christine Duthoit; Catherine Blanpied; Sophie Chabot; Pascale Bouillé; Philippe Lluel; Nathalie Vergnolle; Claire Racaud-Sultan; Audrey Ferrand
Journal:  Int J Cancer       Date:  2019-02-14       Impact factor: 7.396

Review 3.  Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.

Authors:  Ashleigh Parkin; Jennifer Man; Paul Timpson; Marina Pajic
Journal:  FEBS J       Date:  2019-08-05       Impact factor: 5.542

Review 4.  Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review).

Authors:  Elena Bălășescu; Andreea-Cristina Gheorghe; Andreea Moroianu; Gabriela Turcu; Alice Brînzea; Mihaela Antohe; Anastasia Hodorogea; Lorena Manea; Mihaela Balaban; Răzvan Andrei; Ionela Hulea; Cristiana Gabriela Popp; Luciana Nichita; Mirela Daniela Cioplea; Sabina Andrada Zurac; Daniela Adriana Ion; Roxana Ioana Nedelcu
Journal:  Exp Ther Med       Date:  2022-04-11       Impact factor: 2.447

5.  B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer.

Authors:  Ling Wang; Fu-Biao Kang; Chao Yang; Xin-Bo Liu; Li Wang
Journal:  Cancer Cell Int       Date:  2018-07-13       Impact factor: 5.722

6.  Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.

Authors:  Mei-Ren Pan; Cheng-Che Wu; Jung-Yu Kan; Qiao-Lin Li; Shu-Jyuan Chang; Chun-Chieh Wu; Chung-Liang Li; Fu Ou-Yang; Ming-Feng Hou; Hon-Kan Yip; Chi-Wen Luo
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.